Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule du… Read more
Tempest Therapeutics Inc (TPST) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.068x
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has a cash flow conversion efficiency ratio of -1.068x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.78 Million) by net assets ($6.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tempest Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Tempest Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tempest Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempest Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CPH Chemie + Papier Holding AG
LSE:0QNZ
|
0.023x |
|
Trigon Metals Inc
PINK:PNTZF
|
0.323x |
|
Regency Affiliates Inc
PINK:RAFI
|
0.007x |
|
ZUUZF
PINK:ZUUZF
|
-0.034x |
|
Intraco Penta Tbk
JK:INTA
|
-0.008x |
|
Pengana Capital Group Ltd
AU:PCG
|
0.058x |
|
HF Co.
LSE:0EOI
|
-0.021x |
|
Concrete Engineering Products
KLSE:8435
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Tempest Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $19.13 Million | $-33.03 Million | -1.727x | -68.96% |
| 2023-12-31 | $26.77 Million | $-27.36 Million | -1.022x | +40.43% |
| 2022-12-31 | $18.11 Million | $-31.07 Million | -1.716x | -138.72% |
| 2021-12-31 | $36.12 Million | $-25.96 Million | -0.719x | -359.98% |
| 2020-12-31 | $-68.79 Million | $-19.02 Million | 0.276x | +140.15% |
| 2019-12-31 | $59.87 Million | $-41.22 Million | -0.689x | -112.90% |
| 2018-12-31 | $73.12 Million | $-23.65 Million | -0.323x | +76.18% |
| 2017-12-31 | $14.98 Million | $-20.34 Million | -1.358x | -137.97% |
| 2016-12-31 | $108.22 Million | $-61.73 Million | -0.570x | -43.90% |
| 2015-12-31 | $126.85 Million | $-50.29 Million | -0.396x | +28.30% |
| 2014-12-31 | $55.33 Million | $-30.59 Million | -0.553x | -27.42% |
| 2013-12-31 | $41.70 Million | $-18.09 Million | -0.434x | -19.49% |
| 2012-12-31 | $30.72 Million | $-11.16 Million | -0.363x | -- |